|
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
- Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic
- Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung . . .
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Background Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast . . .
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo
|
|
|